Tandem Diabetes Care (TNDM) Cash & Equivalents (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Cash & Equivalents for 14 consecutive years, with $62.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 2.02% year-over-year to $62.8 million; the trailing twelve-month figure through Jun 2026 stood at $62.8 million (down 2.02% YoY), and the FY2025 full-year result was $90.6 million, up 30.91% from the prior year.
• Cash & Equivalents declined to $62.8 million in Q2 2026 per TNDM's latest filing, from $179.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $179.3 million in Q1 2026 and bottomed at $47.7 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $92.7 million across 5 years, with a median of $85.1 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents sank 65.88% in 2023, then soared 234.72% in 2026.
• Over 5 years, Cash & Equivalents stood at $172.5 million in 2022, then tumbled by 65.88% to $58.9 million in 2023, then grew by 17.61% to $69.2 million in 2024, then surged by 30.91% to $90.6 million in 2025, then tumbled by 30.69% to $62.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $62.8 million, $179.3 million, and $90.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.